Pastelín HG, del Valle ML, Tenorio LFA

Language: Spanish
References: 7
Page: 112-115
PDF size: 54.85 Kb.

ABSTRACT

The results of three clinical studies (OVERTURE, ENABLE and RENEWAL), in patients with cardiac failure, are analized from a pharmacological point of view. In the first one of these, the action of an Angiotensin Converting Enzyme inhibitor, that at the same time inhibits the neutral endopeptidase, is studied. In the second, a blockade for endothelin cellular receptors is studied and, in the third, a synthetic aceptor of the a-Tumoral Necrosis Factor is taken into account. In the OVERTURE study, the benefic action of the inhibition of the Angiotensin Converting Enzyme in patients suffering from cardiac failure is confirmed, without a major effect from the neutral endopeptidase derived from its simultaneous inhibition. The other two studies were suspended because of the major side effects. The drugs used in OVERTURE, ENABLE and RENEWAL studies are relevant efforts of molecular design that, without any question, will project into the future of the therapeutic approach of cardiac failure. It is convenient to point out that in the task of designing clinical studies considering cellular signaling systems, there are other venues warranting their use in pathological or natural functions.

REFERENCES

1. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, Wedberg K: Comparison of omopatrilot and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events. Circulation 2002, 106: 920-926.

2. Corti R, Burnett J, Rouleau J: Vasopeptidase inbibitors. A new therapeutic concept in cardiovascular disease? Circulation 2001; 104: 1856-1862.

3. Rouleau J, Pfeffer M, Steward D: Comparison of the vasopeptidase inhibitor omapatrilat and lisinopril on excercise tolerance and morbility in patients with heart failure. IMPRESS randomized trial. Lancet 2000; 4: 85-92.

4. Hurlimann D, Enseleit F, Rodriguez H: Endothelin antagonists and heart failure. Curr Hypertens Rep 2002; 4: 85-92.

5. Tamargo J, Delpon E: Futuro del tratamiento farmacológico de las enfermedades cardiovasculares. En: Bayés de Luna A, López-Sendón J, Attie F, Alegría Esquerra E: Cardiología clínica. Barcelona. Masson 2003, pp 861-882.

6. Feldman A, Combes A, Wagner D: The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35: 537-544.

7. Herrera E, Herrera J, Rodríguez H: Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol 2002; 55: 61-66.